Tian Cuimeng, Liu Guimei, Xu Yongxiang, Xia Guangrong, Zhang Tongmei, Huang Jiaqiang, Liu Fangchao, Li Baolan
Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China.
Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China.
Oncol Lett. 2023 Apr 5;25(5):205. doi: 10.3892/ol.2023.13791. eCollection 2023 May.
The objective of the present study was to investigate the role of postoperative radiotherapy (PORT) after radical resection of stage IIIA-N2 non-small cell lung cancer (NSCLC). Subgroups of patients who benefited from PORT were evaluated. A retrospective review of 288 consecutive patients with resected pIIIA-N2 NSCLC at Beijing Chest Hospital (Beijing, China) was performed. Of these patients, 61 received PORT. The 288 patients were divided into PORT and non-PORT groups according to the treatment received. The baseline characteristics of the two patient groups were balanced using propensity score-matching (PSM; 1:1 matching). In total, 60 patients in the PORT group and 60 patients in the non-PORT group were matched. After PSM, the median survival time of the matched patients was 53 months. The 1-, 3- and 5-year overall survival (OS) rates of the PORT patient group were 95.0, 63.2 and 48.2%, respectively, while those of the non-PORT group were 86.7, 58.3 and 34.5%, respectively, and there was no significant difference between the two groups (P=0.056). The 5-year local recurrence-free survival (LRFS) rate in the PORT group was significantly improved (P=0.001). The effects of PORT on OS and LRFS rates were analysed in patients with different clinicopathological features. For subgroups with multiple N2 stations, N2 positive lymph nodes ≥4 and squamous cell carcinoma, PORT significantly increased the OS and LRFS rates (P<0.05). In conclusion, there was no statistically significant improvement in the 5-year OS rate with PORT overall, but there may be subgroups, such as patients with multiple N2 stations, N2 positive nodes ≥4 and squamous cell carcinoma histology, that could be explored as potentially benefitting from improved 5-year OS and LRFS rates with PORT.
本研究的目的是探讨术后放疗(PORT)在ⅢA-N2期非小细胞肺癌(NSCLC)根治性切除术后的作用。对从PORT中获益的患者亚组进行了评估。对北京胸科医院(中国北京)连续288例接受pIIIA-N2期NSCLC切除术的患者进行了回顾性分析。这些患者中,61例接受了PORT。根据接受的治疗将288例患者分为PORT组和非PORT组。使用倾向评分匹配(PSM;1:1匹配)使两组患者的基线特征达到平衡。PORT组和非PORT组分别有60例患者进行了匹配。PSM后,匹配患者的中位生存时间为53个月。PORT组患者的1年、3年和5年总生存率(OS)分别为95.0%、63.2%和48.2%,而非PORT组分别为86.7%、58.3%和34.5%,两组之间无显著差异(P = 0.056)。PORT组的5年局部无复发生存率(LRFS)显著提高(P = 0.001)。分析了PORT对不同临床病理特征患者的OS和LRFS率的影响。对于多个N2站、N2阳性淋巴结≥4个和鳞状细胞癌的亚组,PORT显著提高了OS和LRFS率(P < 0.05)。总之,总体而言PORT对5年OS率没有统计学上的显著改善,但可能存在一些亚组,如多个N2站、N2阳性淋巴结≥4个和组织学为鳞状细胞癌的患者,可能从PORT改善的5年OS和LRFS率中获益,值得进一步探索。